6970 results about "Screening method" patented technology

The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase.

An e-mail filtering method and system that categorize received e-mail messages based on information about the sender. Data about the sender is contained in the message and is used to identify the actual sender of the message using a signature combining pieces of information from the message header or derived from information in the message header. This and other information about the message is then sent by each member of an e-mail network to one or more central databases (in one embodiment, the information will also be stored at a database associated with the recipient's e-mail program and filtering software) which stores the information and compiles statistics about e-mails sent by the sender to indicate the likelihood that the e-mail is unsolicited and determine the reputation of the sender (a good reputation indicates the sender does not send unwanted messages while a bad reputation indicates the sender sends unsolicited e-mail messages). Information from the central database is then sent to recipients in order to determine the likelihood that a received e-mail message is spam (information may also be obtained from the local database associated with the recipient's e-mail program and filtering software).

A virtual reality (VR)-based test battery wherein various neurobehavioral performance skills, including motor skills, sensory-perceptual skills, attention, and decision-making can be measured in human subjects. The invention can be used as a screening method within a virtual environment to provide an overall measure of general brain function relating to behavioral ability. In addition, the invention provides comprehensive VR-based neurobehavioral examinations tailored to individual subjects which can automatically self-adjust during operation in accordance with the specific purpose of the assessment, or for forms of cognitive or physical rehabilitation. According to the invention, patients with neurological and psychiatric dysfunctions can be assessed with physiologic monitoring as well as with anatomical and functional neuroimaging to non-invasively map the functional neuroanatomic correlates of VR-based test performance. In a preferred embodiment, the VR-based neurobehavioral testing system is portable allowing computerized tests to be administered in a desk-top or lap-top configuration, or via the Internet for tele-assessment of human subjects who are physically inaccessible to the test administrator. In a particularly preferred embodiment, the method of the invention is used for vocational assessment and training, wherein individual test scores are combined into a final metric useful for assessing a candidate's qualifications for employment, or certification in a particular skill.

The present invention provides a non-mouse, including human, pluripotential embryonic stem cell which can:

• • (a) be maintained on feeder layers for at least 20 passages; and
  • (b) give rise to embryoid bodies and multiple differentiated cell phenotypes in monolayer culture.

The invention further provides a method of making a pluripotential embryonic stem cell comprising culturing germ cells and germ cell progenitors in a composition comprising a growth enhancing amount of basic fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.

Also provided are compositions useful to produce the pluripotent embryonic stem cells and methods of screening associated with the method of making the embryonic stem cell.

Massively parallel sequencing of cell-free, maternal plasma DNA was recently demonstrated to be a safe and effective screening method for fetal chromosomal aneuploidies. Here, we report an improved sequencing method achieving significantly increased throughput and decreased cost by replacing laborious sequencing library preparation steps with PCR employing a single primer pair. Using this approach, samples containing as little as 4% trisomy 21 DNA could be readily distinguished from euploid samples.

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

The invention provides a method for constructing a eukaryon gene knockout library by using a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system. The method comprises the following steps: expressing genes encoded with Cas9 and OCT1 (Organic Cation Transporter 1) proteins into a eukaryon cell line; screening to obtain a cell line which stably expresses Cas9; and carrying out library construction and functional screening. The method has the greatest advantages that the method can be applied to most of eukaryon cell lines and is not limited by the specific cell line. Furthermore, the functional screening positive rate is high and the background value is low. According to a large-scale screening method, the cost is greatly reduced; the problems that the time is long and the labor cost is high due to the fact that a single gene knockout cell is prepared are solved.

Cystitis of the bladder and urinary tract, particularly interstitial cystitis, are treated using effective unit doses of chondroitin sulfate. Further, cystitis patients are screened for their response to a given cystitis treatment using a method in which patients are first challenged with an irritant and then treated with a selected cystitis therapeutic. Candidates for further treatment are identified as those patients who on receiving the selected therapeutic, report relief from at least one symptom elicited with the irritant. Also provided are kits comprising solutions for carrying out this screening method.

The invention relates to a method and system for screening face images. The method comprises the following steps: according to preset face integrity standards, face size threshold and face position threshold, obtaining a first screening result; according to a preset definition threshold, obtaining a second screening result; according to a preset best angle threshold, obtaining a third screening result; and according to the sum of similarities between each face image and other face images, the definition of each face image and the face deflection angle, obtaining the weighting sum of each face image in the third screening result, and acquiring a face image with the maximum weighting sum for face identification. The method can be used for solving the problem that the face is mistakenly identified due to the low quality of an input image, the data volume of the face images is effectively reduced, and the operation load during face identification is relieved; and moreover, the data volume of the face images is reduced, front face images with high quality are effectively screened to be identified, and the accuracy and real-time performance of face identification are improved.

The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

The invention provides a genetic screening method for identifying a transfected cell expressing the polypeptide of interest. The methods allows for high throughput screening of recombinant cells for elevated levels of expression of the polypeptide of interest. The invention also provides capture media, formulations and methods of making and using thereof.

It is intended to provide a method of forming pancreatic β cells from mesenchymal cells characterized by comprising using mammal-origin mesenchymal cells as starting cells, culturing these cells in the presence of, for example, a pancreatic β cell-forming agent, and selecting and separating the thus obtained pancreatic βcells with the use of a gene expressed specifically in such cells as a selection marker; a remedy for glucose intolerance which comprises pancreatic β cells obtained by the above method as the active ingredient; a pancreatic β cell-forming agent such as a cytokine to be used in the above method; a method of screening a candidate compound promoting the formation of pancreatic β cells from mesenchymal cells; and a pancreatic β cell formation promoter obtained by this screening method.

A crystalline composition comprising a crystal of the IL-6 receptor I chain is provided. Also provided are methods of using the crystal and related structural information to screen for and design compounds that interact with IL-6R, or variants thereof. Also provided arc methods of modulating an IL-6 receptor comprising contacting the IL-6 receptor with a compound identified by the screening method of the invention.

In compound screening using cell images, compounds having an effective action on cells are searched for by automated processing, to more perform existing methods for compound searching more effectively. There is provided an apparatus including an image-acquisition unit for capturing a plurality of cell images under different image-acquisition conditions; and an analysis unit for extracting a cell position and at least one feature on the basis of the plurality of cell images and for performing statistical analysis with the extracted features serving as parameters.

Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.